| Número de catálogo | HY107026 |
|---|
| Reactividad de especies | Human |
|---|
| Aplicaciones | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Especie huésped | Human |
|---|
| Clonalidad | Monoclonal |
|---|
| Isotipo | IgG |
|---|
| ID de clon | MNAC13 |
|---|
| Actividad biológica |
MNAC13 (200-300 ug/mL, 1 h) specifically binds TrkA and leads to inhibition of NGF-dependent signaling in 3T3 cells overexpressing TrkA [1]. MNAC13 (4 ug/mL, 4 days) effectively blocks NGF induced survival and axonal growth of PC12 cells [2]. MNAC13 (2 or 20 ng/mL) specifically binds to TrkA immune adhesin, but does not bind to TrkB in TrkA-BALB/C 3T3 cells [2]. Western Blot Analysis [1] Cell Line: 3T3 cells overexpressing TrkA Concentration: 200-300 ug/mL Incubation Time: 1 h Result: Significantly inhibited the phosphorylation of TrkA and the phosphorylation level of downstream signaling molecule PLCγ1. MNAC13 (0.9-60 ug; i.p. or s.c.; single dose; 18 h before the formalin test) significantly reduce inflammatory pain in the 5 % formalin solution injected CD1 male mice [1]. MNAC13 (30-70 ug; i.p.; once daily; from day 3 to day 10) significantly reduces neuropathic pain and exhibits long-lasting effects in the chronic constriction injury (CCI) CD1 male mice [1]. MNAC13 (1 ug; i.p.; single dose; 15 min before the test) has a significant synergistic analgesic effect combinated with opioid drugs in the 5 % formalin solution injected CD1 male mice [1]. MNAC13 blocks the effect of TrkA on basal forebrain cholinergic neurons (BFCNs) more significantly and persistently than blocking NGF in MNAC13 hybridoma cells injected Wistar rats [2]. |
| Sistema de expresión |
Mammalian cells |
| Objetivo |
Trk-A, High affinity nerve growth factor receptor, NTRK1, Tropomyosin-related kinase A, Neurotrophic tyrosine kinase receptor type 1, MTC, TRKA, Tyrosine kinase receptor, TRK, p140-TrkA, TRK1-transforming tyrosine kinase protein, gp140trk, Tyrosine kinase receptor A |
| Nivel de endotoxinas |
< 10 EU/mg |
| Pureza |
>95% purity as determined by SDS-PAGE. |
| Purificación |
Protein A/G purified from cell culture supernatant. |
| Número de acceso |
P04629 |
| Forma |
Liquid |
| Buffer de almacenamiento |
0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
|
| Estabilidad y almacenamiento |
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Nombres alternativos | MNAC13 |
|---|
| Fondo | High affinity nerve growth factor receptor (NTRK1/TRKA) is a ~87 kDa protein. Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand. Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival. Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation. 5. Hempstead, BL. et al. (1991) Nature 350, 678-83. PMID: 18508216. Tong, Q. et al. (2012) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 26, 3811-21. PMID: 226490327. Anta, B. et al. (2016) The Journal of biological chemistry 291, 19132-45. PMID: 274453388. Barker, PA. et al. (1993) The Journal of biological chemistry 268, 15150-7. PMID: 8325889 |
|---|
| Referencias |
1. Ugolini G, et al. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2985-90. [HY107026]
2. Cattaneo A, et al. Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. J Neurosci. 1999 Nov 15;19(22):9687-97. [HY107026] |
| Nota |
For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control |
Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
中文
English
한국어
日本語
Español
Français
Русский
